Identification of new molecular targets for the treatment of breast cancer is an important clinical goal, especially for triplenegative breast cancer, which is refractory to existing targeted treatments. The aryl hydrocarbon receptor (AhR) is a ligandactivated transcription factor known primarily as the mediator of dioxin toxicity. However, the AhR can also inhibit cellular proliferation in a ligand-dependent manner and act as a tumor suppressor in mice, and thus may be a potential anticancer target. To investigate the AhR as an anticancer target, we conducted a small molecule screen to discover novel AhR ligands with anticancer properties. We identified raloxifene, a selective estrogen receptor (ER) modulator currently used in the clinic for prevention of ER-positive breast cancer and osteoporosis in post-menopausal women, as an AhR activator. Raloxifene directly bound the AhR and induced apoptosis in ER-negative mouse and human hepatoma cells in an AhR-dependent manner, indicating that the AhR is a molecular target of raloxifene and mediates raloxifene-induced apoptosis in the absence of ER. Raloxifene selectively induced apoptosis of triple-negative MDA-MB-231 breast cancer cells compared with non-transformed mammary epithelial cells via the AhR. Combined with recent data showing that raloxifene inhibits triple-negative breast cancer xenografts in vivo (Int J Oncol. 43(3):785-92, 2013), our results support the possibility of repurposing of raloxifene as an AhRtargeted therapeutic for triple-negative breast cancer patients. To this end, we also evaluated the role of AhR expression on survival of patients diagnosed with breast cancer. We found that higher expression of the AhR is significantly associated with increased overall survival and distant metastasis-free survival in both hormone-dependent (ER-positive) and hormoneindependent (ER and progesterone receptor (PR)-negative) breast cancers. Together, our data strongly support the possibility of using the AhR as a molecular target for the treatment of hormone-independent breast cancers.
1
The role of the AhR in carcinogenesis continues to evolve. The prototypical AhR ligand 2,3,7,8-Tetrachlorodibenzo-pdioxin (TCDD) acts as a tumor promoter in rodent models; [2] [3] [4] [5] however, there is no direct evidence that AhR promotes tumorigenesis in humans. On the contrary, several liganddependent and -independent AhR tumor-suppressive functions have been identified. AhR knockout TRAMP (transgenic adenocarcinoma of the mouse prostate) mice develop tumors with increased severity and frequency compared with AhRexpressing counterparts, 6 and treatment of TRAMP mice with the AhR ligand 6-methyl-1,3,8-trichlorodibenzofuran (6-MCDF) reduces the frequency of prostate metastases. 7, 8 Likewise, formation of diethyl nitrosamine (DEN)-induced liver tumors is accelerated in the absence of the AhR in a ligandindependent manner. 9 Similarly, AhR null mice 10 develop cecal tumors, whereas WT AhR mice do not, which is further potentiated in the ApcMin/ þ model of intestinal cancer. 11 At the molecular level, the AhR inhibits cellular proliferation by inducing p27
Kip1 expression, 12 and deletion of the AhR ligandbinding domain results in constitutively active AhR that induces apoptosis in Jurkat T-lymphocytes. 13 Taken together, these data highlight distinct pathways by which AhR can function as a tumor suppressor.
Investigation of the AhR as an anticancer target as well as identification and testing of novel anticancer AhR ligands lacking dioxin-like toxicity is a major goal of our laboratory. Identification of activators of AhR-mediated transcription from existing FDA-approved drugs may significantly expedite this goal by identifying new indications, thereby re-tooling old drugs for a new anticancer target. Importantly, the AhR is activated by a structurally diverse array of ligands, 14, 15 some of which have known anticancer effects. [16] [17] [18] [19] We previously used a small molecule-screening approach to identify the immunomodulatory drug leflunomide as an AhR ligand with antiproliferative effects in melanoma cells. 19 Using the same approach, we identified raloxifene (Evista) as an activator of AhR signaling.
Raloxifene is a selective estrogen receptor (ER) modulator currently used in the clinic for the chemoprevention of osteoporosis. Identified through a structure activity study of a series of 3-aroyl-2-arylbenzo [b] thiophene derivatives aimed at identifying non-steroidal anti-estrogens, 20 raloxifene was found to inhibit the growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumors and reverse the inhibitory effect of 17b-estradiol (E2) on ovine prolactin-stimulated a-lactalbumin production. [20] [21] [22] Subsequent studies verified the weak estrogenic potential of raloxifene, as well as the ability to inhibit bone loss in ovariectomized rats and reduce risk of vertebral fractures in post-menopausal women with osteoporosis. [23] [24] [25] Prior to 2007, the only approved-indication of raloxifene was for prevention and treatment of osteoporosis; however, the results of the study of tamoxifen and raloxifene (STAR) trial demonstrated that raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and is associated with decreased risk of fractures and stroke compared with tamoxifen. 26, 27 Thus, raloxifene is also used in the prevention of breast cancer in post-menopausal women with increased risk of developing the disease. 23, 27 Raloxifene inhibits the growth of carcinogen-induced mammary tumors in mice. 20, 21, 28 In addition, ER-independent effects of raloxifene have been demonstrated in prostate and breast cancer cells. [29] [30] [31] [32] Based on our small molecule-screening results, we investigated whether raloxifene had anticancer effects mediated through the AhR, and found that it induces apoptosis in an AhR-dependent manner. Our results suggest that the AhR can be targeted to induce apoptosis in ER-negative breast cancer cells, which may have important clinical implications for the treatment of both hormoneindependent and triple-negative breast cancers expressing the AhR.
Results
Raloxifene induces transcriptional activation of the AhR. We conducted a small molecule screen to identify novel activators of AhR-mediated transcription. Breast cancer drug raloxifene was identified in this screen and elicited a dose-dependent activation of XRE-driven luciferase reporter ( Figure 1a ). We were immediately interested in the possibility of AhR-dependent effects of raloxifene in ER-negative breast cancer cells. To evaluate this possibility we used ER-negative MDA-MB-231 breast cancer cells, which express similar levels of AhR as mouse and human hepatoma cell lines (Figure 1b) . We then characterized the profile of AhR activation by raloxifene in these cell lines. In both Hepa1 and MDA-MB-231 cells, raloxifene induced AhR nuclear localization similar to TCDD (Figures 1c and d) . Interestingly, AhR exhibited partial nuclear localization in MDA-MB-231 cells in the absence of ligand, which was potentiated by TCDD and raloxifene (Figure 1d ). We next evaluated the ability of raloxifene to activate the endogenous AhR target genes CYP1A1 and NQO1 by semi-quantitative RT-PCR. Raloxifene significantly increased the expression of these genes in Hepa1 cells (Figure 1e ). Activation of both CYP1A1 and NQO1 required functional ARNT (Figure 1f) , indicating the requirement for canonical AhR signaling. Raloxifene significantly increased the expression of CYP1A1 in both human HepG2 hepatoma cells (Figure 1g ) and MDA-MB-231 breast cancer cells (Figure 1h ). Taken together, these results indicated that raloxifene activates AhR signaling in liver and breast cancer cells.
Raloxifene is an AhR ligand. To determine whether raloxifene is a ligand of the AhR, we first performed molecular docking studies with raloxifene using an optimized homology model of the human AhR ligand-binding pocket. A raloxifene-guided optimization step of the model previously developed in our laboratory 33 produced significant changes at the level of volume and area of the binding pocket, which were attributed to the different size and shape of raloxifene compared with the planar and symmetric TCDD scaffold (Figure 2a ). The optimized binding pocket extended towards the Gb and Ib sheets in order to allocate the 4-hydroxyphenyl-benzothiophene and piperidyl rings of raloxifene (Figure 2a) . TCDD was able to dock into the pocket with a score of À 21.8, establishing a hydrogen bond (HB) between oxygen and the side chain of Gln 383 (Ib) (Figure 2b ). Instead, raloxifene docked with the lower score of À 10.3 exhibiting a binding pattern different from that of TCDD, as it did not involve Gln 383 (Ib) due to unfavorable energy in that conformation. Raloxifene established HB interactions with a ketone carbonyl, the thiol group of Cys 333 (Fa), and the 6-hydroxyl and carbonyl of the backbone of Ile 349 (Gb) and Val 363 (Hb), respectively ( Figure 2b ). The docking scores obtained predicted a lower binding affinity for raloxifene than TCDD, which was consistent with the higher concentrations of raloxifene needed to activate the AhR (Figure 1) .
We next used a ligand competition assay employing cytosolic extracts from ER-negative, AhR-expressing Hepa1 cells and radiolabeled 3- (Figure 2c ), suggesting that raloxifene binds the AhR. To provide additional evidence of direct binding, we evaluated the ability of raloxifene to delay subtilisin-mediated proteolysis of the AhR. Incubation of in vitro translated AhR with raloxifene resulted in delayed AhR proteolysis and differential formation of proteolysis products (Supplementary Figure S1) . Taken together, these data suggest that raloxifene is a ligand of the AhR.
Raloxifene induces cell death in human hepatoma and breast cancer cells. During characterization of AhR activation by raloxifene, we observed inhibition of growth and signs of cell death in Hepa1, HepG2, and MDA-MB-231 cells. Specifically, treatment with raloxifene for 48 h induced dramatic cell death evidenced by cell rounding, membrane blebbing, and loss of plate adhesion (Figure 3a) . Overnight incubation of MDA-MB-231 cells with raloxifene induced similar effects, with clear evidence of apoptosis as indicated by nuclear condensation and fragmentation (Figure 3b ). These data suggested that raloxifene induces a growth inhibitory effect in both hepatoma and ER-negative breast cancer cells. We also performed cell viability assays to quantitatively assess the effects of raloxifene. Requirement of AhR expression for Raloxifene-induced apoptosis in hepatoma cells. Having determined that raloxifene is both an AhR ligand and induces significant growth inhibition and apoptosis in mouse Hepa1 and human HepG2 and MDA-MB-231 cells at concentrations consistent with AhR activation, we next determined whether AhR signaling mediates both the antiproliferative and apoptotic effects of raloxifene. To investigate the role of AhR in mediating the effects of raloxifene in hepatoma cells, we assessed cell viability and apoptosis of hepatoma cells with differential AhR expression after treatment with raloxifene. We first employed the rat hepatoma cell culture model of 5L and BP8 cells, which are AhR-positive and AhR-negative, respectively, and have been used previously to demonstrate the AhR-dependent antiproliferative effects of the AhR ligand TCDD. 12, 35, 36 AhR-deficient BP8 cells treated with raloxifene exhibited significantly higher BrdU incorporation than AhR-expressing 5L cells (Figure 3e ). Consistent with these data, Hepa1 cells exhibited decreased viability compared with derivative TAO cells that have 90% reduced AhR expression (data not shown). We also employed an independently generated set of mouse hepatoma cell lines with low-AhR expression (C12) and C12 þ AhR cells, which are stably transfected with mouse AhR. 37 The viability of C12 þ AhR cells was significantly decreased upon treatment with raloxifene compared with C12 cells (Figure 3f ). Induction of AhR target genes by raloxifene required expression of the AhR heterodimerization partner ARNT (Figure 1f ). To determine whether induction of apoptosis by raloxifene in hepatoma cells also required canonical AhR signaling, we evaluated the effect of ARNT expression on raloxifene-mediated cell death. Consistent with gene induction data, cells expressing functional ARNT showed significantly decreased proliferation compared with C4 cells (data not shown).
We next determined the extent to which apoptosis contributes to raloxifene-induced growth inhibition in mouse hepatoma cells. Raloxifene strongly induced apoptosis after 48 h of treatment compared with vehicle-treated Hepa1 cells (% nuclear fragmentation for vehicle: 4.7 ± 1.8; raloxifene: 47.0±4.0, P ¼ 0.0007) (Supplementary Figure S3) .
Despite the ability of TCDD to strongly activate AhR signaling, TCDD did not induce apoptosis (data not shown), suggesting a ligand-specific effect. AhR expression was required for increased apoptosis in Hepa1 cells compared with TAO cells (Figures 4a and b) , strongly suggesting that the effects were AhR-dependent. To confirm these findings, we analyzed the effects of raloxifene on induction of apoptosis in C12 and C12 þ AhR cells. Consistent with the observed decreases in cell viability, re-expression of AhR in C12 cells rescued induction of apoptosis by raloxifene (Figure 4c ). Likewise, apoptosis induced by raloxifene was significantly increased in vT{2} cells compared with C4 cells (Figure 4d ). Taken together, these results indicated that induction of apoptosis by raloxifene in mouse hepatoma cells was significantly dependent on the activity of both AhR and ARNT.
Having shown that the induction of apoptosis by raloxifene required AhR expression in Hepa1 cells, we next confirmed the effects in human cell lines. The extent of apoptosis induced by raloxifene in HepG2 cells was similar to that of Hepa1 cells (Supplementary Figure S3) . To further evaluate the AhR-dependent effects of raloxifene in hepatoma cells, the effects of raloxifene were tested on human HepG2 cells stably expressing scrambled shRNA (shScram) or AhR shRNA (shAhR) ( AhR is a potential molecular target for the treatment of ER-negative breast cancer. Our results indicated that raloxifene induces apoptosis in ER-negative breast cancer cells in an AhR-dependent manner. To determine the utility of the AhR an anticancer target, we next determined whether AhR is expressed in different breast cancer subtypes. We also investigated the prognostic value of AhR expression in different breast cancer subtypes in terms of overall survival, distant metastasis-free survival, and relapse-free survival using a breast cancer-specific Kaplan-Meier Plotter analysis tool. 38 We found that higher AhR expression was associated with statistically significant increased overall survival and distant metastasis-free survival (Figures 7a  and b) . In addition, these data indicate that AhR is expressed in both ER-positive and ER-negative cancers (Figures 7 and 8) .
We found that high expression of the AhR strongly correlated with better patient survival in several breast cancer contexts. For example, in a population of 1027 breast cancer patients, those in the upper 75% based on AhR expression exhibited better overall survival (Figure 7a, Po0.05) . Here, the hazard ratio (HR) serves as an indication of patient prognosis, with HR values o1 indicating better survival. Further analysis showed that distant metastasis-free survival in all breast cancer patients (n ¼ 1353) based on the upper 75% of AhR expression was associated with a 1.41-fold improved prognosis (HR À 1 , P ¼ 0.0046; Figure 7b ). Interestingly, the prognostic value of the AhR expression was significantly better for ER-positive breast cancer than ERnegative breast cancer. The expression of AhR is associated with increased overall survival, distant metastasis-free survival, and relapse-free survival in ER-positive breast cancer (Figures 7d-f) . Further, the log-rank P significance of distant metastasis-free survival in patients reached 2.6e À 7 based on immunotyped ER-positive expression and high AhR To look specifically at hormone-independent breast cancer subtype, we evaluated the effect of progesterone receptor (PR) expression in addition to that of ER. In ER-and PRnegative breast cancer, relapse-free survival was significantly improved for the upper two-thirds of patients based on AhR expression (Figure 8a , HR À 1 ¼ 2.22, P ¼ 0.0021). We also investigated relapse-free survival in specific breast cancer subtypes based on the St. Gallen criteria, 39 comprising Luminal types A and B, HER2 þ , and basal subtypes (Supplementary Figure S5) . Luminal type A breast cancer exhibited a statistically significant difference between AhR high and low expression groups. In addition, there was a modest improvement in relapse-free survival in patients with high AhR expression in the basal subset. Taken together, our data suggest that AhR expression in both hormone-dependent and -independent cancers is associated with improved patient survival in certain contexts. Targeting these patient subsets with AhR-mediated therapeutics (such as raloxifene) is thus an exciting possibility for improving patient outcome.
Discussion
In the pursuit of new treatments for breast cancer, it is vital not only to develop new therapeutic agents for known drug targets, but also to identify and characterize novel molecular targets of existing drugs for re-tooling in order to expand the arsenal of treatment options available to breast cancer patients. While the AhR has been studied in the past as the mediator of TCDD toxicity 1, 10, 40, 41 as well other environmental carcinogens, recent studies strongly suggest that the AhR has the potential to be an effective target for cancer therapeutics. 6, 7, 16, 17, [42] [43] [44] [45] [46] [47] A structurally diverse array of small molecules, some of which are used in the clinic, have been shown to be ligands of the AhR. 14, 15, 19, 46 Likewise, several compounds have been developed as selective modulators of the AhR, some of which show promise as anticancer agents. 17 In the present study, we screened a library of pharmacologically active compounds to identify putative AhR ligands. This targeted screening approach was intentional, as identification of novel AhR activators from compounds with established clinical activity may expedite the AhR-based drug discovery process. 19 During characterization of lead compounds, we found that raloxifene, a selective ER modulator used in the clinic is an AhR ligand (Figure 2 ) that activates AhR signaling (Figure 1) . We evaluated the effects of raloxifene in Hepa1 and HepG2 cells and found that raloxifene decreased cell viability by inducing apoptosis in an AhR-dependent manner (Figures 3-5) . Despite the strong AhR-dependent induction of apoptosis, we also found that overall cell viability was decreased in both AhR expressing and paired low/nonexpressing cells, which likely reflected a combination of residual AhR expression in knockdown cell lines and AhRindependent effects of raloxifene.
AhR-dependent apoptosis induced by raloxifene in ERnegative hepatoma cells were extendable to MDA-MB-231 breast cancer cells. Specifically, both transient and stable AhR knockdown in MDA-MB-231 cells revealed that induction of apoptosis by raloxifene was significantly dependent upon AhR expression (Figures 6a-d) . Comparison of the antiproliferative effects of raloxifene in non-transformed MCF-10A cells and MDA-MB-231 breast cancer cells showed that the latter had increased sensitivity to raloxifene, despite similar levels of AhR expression (Figure 6e ). This was especially important given that the concentrations of raloxifene used in our study were higher than the bioavailable concentrations achieved using the standard dosing regimen of raloxifene (60 mg per day). It is unknown whether AhR-activating concentrations of raloxifene in ER-negative breast cancer patients can be achieved; however, animal testing indicates that acute dosing of raloxifene is very well tolerated, with no adverse effects of the drug observed at single oral doses of raloxifene up 5000 mg/kg in rats and mice and 1000 mg/kg in monkeys (Evista product insert). Further, a study evaluating bone turnover, serum lipids, and endometrium in postmenopausal women showed that raloxifene is well tolerated up to 600 mg/kg/day for 8 weeks. 48 These results were confirmed in a subsequent 8-week study of 63 postmenopausal women, given 600 mg/kg/day raloxifene. 49 In support of the possibility of using raloxifene for the treatment of ER-negative breast cancer, a study published while this manuscript was in review showed that raloxifene given daily by oral route to mice inhibits xenografts of triple-negative MDA-MB-231 and MDA-MB-468 breast cancer cells and also induces modest tumor regression of MDA-MB-468 cell xenografts. 50 Having identified an AhR-dependent apoptotic effect of raloxifene in triple-negative MDA-MB-231 breast cancer cells, we investigated at the ability of AhR expression to predict relapse-free survival of patients. Specifically, evaluation of relapse-free survival in breast cancer patients indicated that 
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AhR-mediated apoptosis by raloxifene EF O'Donnell et al higher levels of AhR are associated with better overall survival compared with those expressing lower levels of AhR (Figure 7a ). In extending these results to ER-positive and ER-negative breast cancer subsets, we found that higher AhR expression was significantly associated with better relapsefree survival, overall survival, and distant metastasis-free survival in ER-positive breast cancers, strongly supporting a tumor suppressor role of the AhR (Supplementary Figures  S4A-C and Figures 7e and f) . Further, while patients with ERnegative breast cancers exhibited mixed effects with respect to AhR expression on survival outcomes (Figure 7 , lower panels, and Supplementary Figures S4D-F) , specific analysis of ER-and PR-negative breast cancers revealed a significant association between high AhR expression and better relapsefree survival (Figure 8 ). These data support a tumor suppressor role of the AhR in ER-positive and ER-and PRnegative breast cancer subsets. Thus, patients with hormoneindependent breast cancers and high AhR expression may be uniquely primed for treatment with AhR modulators that activate its tumor-suppressive functions.
In conclusion, our data indicate that raloxifene is a novel ligand of the AhR and induces AhR-dependent apoptosis in ER-negative hepatoma and breast cancer cells. These results open up the possibility of re-tooling raloxifene for treatment of patients diagnosed with hormone-independent or triple-negative breast cancers. In the context of ER-and PR-negative breast cancer, the identification of the AhR as a novel anti-breast cancer target has important therapeutic implications -namely, identification of ligands of the AhR with functional effects similar to those of raloxifene. Such molecules would represent a new class of therapeutics specifically for AhR-expressing cancers such as triplenegative breast cancers.
Materials and Methods
Cell lines and reagents. All cells (except MCF10) were cultured in DMEM (Mediatech, Manassas, VA, USA) supplemented with 10% FBS (Tissue Culture Biologicals, Seal Beach, CA, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin (Mediatech). MCF-10A cells were cultured with DMEM/F12 supplemented with 5% horse serum (Invitrogen, Carlsbad, CA, USA), 20 ng/ml EGF, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, and 10 mg/ml insulin, 100 U/ml penicillin, and 100 mg/ml streptomycin. All cells were grown at 37 1C in a humidified 5% CO 2 atmosphere. Raloxifene was purchased from Enzo (Plymouth Meeting, PA, USA). All other reagents were purchased from Sigma (St Louis, MO, USA).
AhR activation assays. Reporter gene assays, immunofluorescence studies for AhR localization, semi-quantitative Real Time PCR for analysis of raloxifene-mediated induction of AhR target genes in Hepa1, MDA-MB-231, and HepG2 cells were conducted as previously described. 19, 33 Primer sequences for mouse and human GAPDH, CYP1A1, and NQO1 have been described previously. 19 To evaluate the requirement for ARNT, we employed a pair of mouse hepatoma cells, one of which expresses a transcriptionally inactive mutant ARNT protein (C4 cells), and C4 cells stably re-expressing WT ARNT (vT{2} cells).
Homology modeling. The homology model of human AhR-LBD bound to TCDD was initially built as described previously by our laboratory. 33 The complex was then submitted to 10 5 steps of ligand-protein side chain optimization using Monte Carlo (MC) simulation in the internal coordinate space with Molsoft ICM. 51, 52 The resulting best energy conformation was then used to dock raloxifene.
The resulting complex with docked ligand submitted again to 10 4 steps of MC ligand-protein side chain optimization to reach the most energetically favorable conformation of the AhR-LBD bound to raloxifene. Molecular Docking of AHR agonists TCDD and raloxifene was performed as described previously. 33 In the ICM-VLS (Molsoft ICM)-screening procedure, the ligand scoring is optimized to obtain maximal separation between the binders and non-binders. Each compound is assigned a score according to its fit within the receptor; this ICM score accounts for continuum and discreet electrostatics, hydrophobicity, and entropy parameters. 51, 53 Competitive binding assays. Competitive binding assays were performed as described previously. 34 ER-negative WT Hepa1 cells served as the source of the whole-cell extract used for the assays and was prepared as described previously. Western blot analysis. Western blot analysis for relative AhR expression was performed as described previously. 18, 33 AhR knockdown. HepG2 and MDA-M231 cells stably expressing shRNAs for constitutive (pLKO.1) and inducible (pTRIPZ) knockdown of AhR were generated as described previously. 18 Briefly, lentiviral particles were produced in HEK293T cells via transfection of packaging and envelope vectors psPAX2 and pMD2.G, respectively. AhR knockdown was routinely confirmed by western blot.
For transient knockdown of AhR in MDA-MB-231, cells were transfected using Dharmafect transfection reagent and siRNA duplexes against luciferase (siLuc, control) or human AhR (siAhR) (Thermo Scientific, Waltham, MA, USA). Knockdowns of AhR of greater than 75% were achieved within 24 h after transfection, and treatments were begun within 24-48 h, depending on cell density. Knockdowns were verified by western blot.
Proliferation and apoptosis assays. Cell viability was assayed using either the CellTiter AQueous Non-Radioactive Cell Proliferation Assay (MTS, Huntsville, AL, USA) or CellTiter Luminescent Cell Viability Assay (Promega, Madison, WI, USA) as described previously. 18 BrdU incorporation was assayed using a BrdU Cell Proliferation Assay according to the manufacturer's suggested protocol (Calbiochem, Billerica, MA, USA). Real time analysis of cellular proliferation by xCELLligence assay was performed as described previously. 
